
The timing of postmenopausal hormone therapy (HT) significantly impacts coronary risk and overall benefit-to-risk profile, according to an overview of Women’s Health Initiative (WHI) results in the journal Menopause.
The timing of postmenopausal hormone therapy (HT) significantly impacts coronary risk and overall benefit-to-risk profile, according to an overview of Women’s Health Initiative (WHI) results in the journal Menopause.
Long-acting reversible contraception (LARC) use among sexually active female adolescents in Rochester, New York, rose from about 4% before a local community intervention to roughly 24% after the initiative.